Oculis Holding AG Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
10.1%projected annual EPS growth
Analyst Coverage
11analysts covering
FY Revenue (est.)
$1Mnext fiscal year
FY EPS (est.)
-$2.23next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
Monitoring Framework
Key Performance Indicators
Cash and Short-Term Investments Quarterly213MTarget: Sufficient to fund operations into 2H 2029
Licaminlimab PREDICT-1 Trial Enrollment & Topline Readout AnnuallyTarget: Topline results expected in Q4 2026 / early 2027
Privosegtor PIONEER-1 Trial Initiation QuarterlyTarget: First patient visit imminent
Watch Items
- Licaminlimab (PREDICT-1) Phase 3 Topline DataTrigger: Efficacy endpoints met in TNFR1-positive dry eye disease patientsAction: Re-evaluate commercialization strategy and potential licensing partnerships
- Privosegtor (PIONEER-1 & PIONEER-2) Clinical ProgressTrigger: Successful patient recruitment and safety profile confirmation in optic neuritisAction: Monitor regulatory alignment with FDA Breakthrough and EMA PRIME designations
- Securities Litigation and InvestigationsTrigger: Material developments or settlements regarding the DIAMOND trial failure disclosuresAction: Assess potential financial liabilities and impact on corporate reputation
Research as of 19 Jun 2026